Nuritas Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 73

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 20

Nuritas General Information

Description

Developer of a biotechnology platform designed to extract peptides from food sources. The company's platform combines artificial intelligence and genomics to discover and unlock natural bioactive peptides with health benefits, enabling businesses to make the food system more sustainable by replacing unwanted ingredients and molecules with more natural and sustainable ones.

Contact Information

Website
www.nuritas.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Joshua Dawson House
  • Dawson Street
  • Dublin D02 RY95
  • Ireland
+353 (01)
Primary Industry
Discovery Tools (Healthcare)
Corporate Office
  • Joshua Dawson House
  • Dawson Street
  • Dublin D02 RY95
  • Ireland
+353 (01)

Nuritas Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuritas Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Secondary Transaction - Private Completed Generating Revenue
13. Accelerator/Incubator 01-Jan-2026 Completed Generating Revenue
12. Accelerator/Incubator 08-Jul-2025 Completed Generating Revenue
11. Later Stage VC (Series C) 20-Dec-2024 Completed Generating Revenue
10. Accelerator/Incubator Completed Generating Revenue
9. Secondary Transaction - Private 02-Nov-2022 Completed Generating Revenue
8. Later Stage VC (Series B) 11-Nov-2021 Completed Generating Revenue
7. Debt - General 28-Nov-2018 Completed Generating Revenue
6. Early Stage VC (Series A) 21-Dec-2017 $18.5M $23.8M Completed Generating Revenue
5. Seed Round 07-Dec-2016 $2.07M $5.35M Completed Generating Revenue
To view Nuritas’s complete valuation and funding history, request access »

Nuritas Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series B
Series B
Series A1
Series A 30,114 $0.001159 $107.55 $107.55 1x $107.55 5.14%
Ordinary 19,000 $0.001159 $1.16 $1.16 1x $1.16 3.24%
To view Nuritas’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nuritas Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology platform designed to extract peptides from food sources. The company's platform combines ar
Discovery Tools (Healthcare)
Dublin, Ireland
73 As of 2026

Cambridge, United Kingdom
 

Wilmington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nuritas Competitors (4)

One of Nuritas’s 4 competitors is Abcam, a Corporate Backed or Acquired company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abcam Corporate Backed or Acquired Cambridge, United Kingdom
Charles River Laboratories International Formerly PE-Backed Wilmington, MA
Q Laboratories Private Equity-Backed Cincinnati, OH
Apeptico Formerly VC-backed Vienna, Austria
To view Nuritas’s complete competitors history, request access »

Nuritas Patents

Nuritas Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4828704-A2 Angiotensin-converting enzyme (ace) inhibiting peptides Pending 20-Dec-2023
AU-2024405811-A1 Angiotensin-converting enzyme (ace) inhibiting peptides. Pending 20-Dec-2023
WO-2025133254-A2 Angiotensin-converting enzyme (ace) inhibiting peptides. Inactive 20-Dec-2023
WO-2025133254-A3 Angiotensin-converting enzyme (ace) inhibiting peptides. Inactive 20-Dec-2023
AU-2024402215-A1 Sleep promoting peptides and the use thereof Pending 20-Dec-2023 C07K7/06
To view Nuritas’s complete patent history, request access »

Nuritas Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuritas Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
Plug and Play Accelerator/Incubator
pladis Foods Accelerator/Incubator Minority
McWin Capital Partners PE/Buyout Minority
M&G Asset Manager Minority
CJ Corporation Minority
You’re viewing 5 of 20 investors. Get the full list »

Nuritas Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Nuritas Uk London, United Kingdom 2018

Nuritas FAQs

  • When was Nuritas founded?

    Nuritas was founded in 2014.

  • Where is Nuritas headquartered?

    Nuritas is headquartered in Dublin, Ireland.

  • What is the size of Nuritas?

    Nuritas has 73 total employees.

  • What industry is Nuritas in?

    Nuritas’s primary industry is Discovery Tools (Healthcare).

  • Is Nuritas a private or public company?

    Nuritas is a Private company.

  • What is Nuritas’s current revenue?

    The current revenue for Nuritas is .

  • How much funding has Nuritas raised over time?

    Nuritas has raised $150M.

  • Who are Nuritas’s investors?

    Plug and Play, pladis Foods, McWin Capital Partners, M&G, and CJ are 5 of 20 investors who have invested in Nuritas.

  • Who are Nuritas’s competitors?

    Abcam, Charles River Laboratories International, Q Laboratories, and Apeptico are competitors of Nuritas.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process